Back

Risk of hyperkalemia with sacubitril/valsartan vs. RAAS inhibitor use in heart failure with reduced and preserved ejection fraction: a meta-analysis of 6 RCTs including 17,362 patients

29 June 2021 (08:00 - 23:59)
Organised by:
Congress Presentation Part of: ePoster session Angiotensin-Renin-Bradykinin System HFA Premium Access Heart Failure 2021

About the speaker

Photo
Doctor Josip Andjelo Borovac

University Hospital Centre Split, Split (Croatia)

738 More presentations in this session

Presentation thumbnail
Atrial lead insertion during cardiac implantable electronic devices implantation in patients with atrial arrhythmia on hospital admission, when does the struggle for sinus rhythm make sense?
Assistant Professor N. Radovanovic (Belgrade, RS)
Abstract Slides
Presentation thumbnail
Features of the remodeling of atria and pulmonary veins in CHF patients with paroxysmal AF and permanent AF
Assistant Professor V. Kirillova (Ekaterinburg, RU)
Abstract Slides
Presentation thumbnail
Rhythm control versus rate control in patients with atrial fibrillation and heart failure across the left ventricular ejection fraction spectrum
Doctor D. Moysidis (Zurich, CH)
Abstract Slides
Presentation thumbnail
Impact of cardiac contractility modulation on ventricular rhythm and conduction disorders in patients with heart failure with reduced ejection fraction and various forms of atrial fibrillation
Doctor A. Safiullina (Moscow, RU)
Abstract Slides
Presentation thumbnail
Was a difference between late and early new-onset of atrial fibrillation in non st-elevation myocardial infarction?
Doctor H. Santos (Lisboa, PT)
Abstract Slides

Access the full session

Session thumbnail
ePoster session

The Event

Event poster

Heart Failure 2021

29 June 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of sacubitril valsartan in heart failure compared to renin angiotensin aldosterone system inhibitors: a systematic review and meta analysis of randomised controlled trials
26 August 2022
thumbnail
Webinar
How to optimise RAASi therapy in patients with hyperkalaemia
15 December 2021
thumbnail
Congress Presentation
Dyskalemias in hypertensive patients treated with combination of antihypertensive drugs: a nested case-control study using danish national registries
1 September 2019
thumbnail
Congress Presentation
Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF
29 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources